EGFR and non-small cell lung carcinoma: Considering that major driver mutations in NSCLC, such as EGFR and KRAS mutations, induce EREG overexpression and activate EGFR pathways through an autocrine loop mechanism, EREG could be an attractive therapeutic target for NSCLC.